[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Paracelsus Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":134},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,76,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100617185","assessing-functional-impairments-in-patients-with-chemotherapy-induced-peripheral-neuropathy-100617185",false,"NCT07315334","Assessing Functional Impairments in Patients With Chemotherapy-Induced Peripheral Neuropathy","Assessing Functional Impairments in Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)","Assess CIPN","Inclusion Criteria:\n\n\\- Male and female patients with CIPN grade ≥ 2, according to Common Terminology Criteria for Adverse Events for peripheral sensory or motor neuropathy (CTCAE) version 5\n\n\\- Age ≥ 18\n\n\\- Ongoing or completed neuropathy-inducing chemotherapy\n\n\\- Ability to stand and walk\n\n\\- Ability to fill out a questionnaire Inclusion criteria for healthy controls\n\n\\- Male and female adults (age ≥ 18)\n\n\\- Ability to stand and walk\n\n\\- Ability to fill out a questionnaire\n\nExclusion Criteria:\n\n* Pre-existing clinically manifest peripheral neuropathy prior to start of chemotherapy (e.g. caused by radiation or malignant plexopathy, lumbar or cervical radiculopathy, carpal tunnel syndrome, B12 deficiency, AIDS, monoclonal gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism or hypothyroidism, inherited neuropathy, etc.)\n\nAcute or chronic injuries\u002F diseases of the musculoskeletal system affecting functional tests\n\n\\- Acute or chronic cardiovascular diseases affecting functional tests\n\n\\- Neurological disease affecting functional tests (for healthy controls)\n\n\\- Neurological disease other than CIPN affecting functional tests (for CIPN patients)",true,"ALL","18 Years",{"count":21,"type":22},80,"ESTIMATED","OBSERVATIONAL","Chemotherapy-induced peripheral neuropathy (CIPN) is a severe side effect of several anti-cancer agents. Typical symptoms include tingling and hypoesthesia in the fingertips and\u002For toes, which substantially impair patients' quality of life and independence. Providing effective, evidence-based treatments for CIPN remains a major challenge in clinical practice. In a recent randomized clinical trial, our group demonstrated the effectiveness of electrotherapy in reducing both sensory and motor symptoms, as assessed by the EORTC-QLQ-CIPN20 questionnaire and CIPN grading according to CTCAE. However, these findings were based exclusively on patients' subjective self-reports (EORTC QLQ CIPN 20 and C-30). To more objectively evaluate treatment success, functional assessments that capture impairments in daily activities are needed.\n\nIn this cross-sectional comparison, we will conduct comprehensive functional assessments and correlate the results with patients' subjective ratings using the EORTC-QLQ-CIPN20, QLQ-C30, and CTCAE v5.0 grading. In addition, data from matched healthy controls will be collected and compared with those of CIPN patients. The findings of this study will contribute to the development of objective measures of functional limitations caused by CIPN and provide a valuable complement to patient-reported outcome obtained through validated questionnaires.",[26],"Chemotherapy Induced Peripheral Neuropathy (CIPN)",[28],"CIPN, EORTC CIPN20, gait , balance, functional assessment, 9 hole peg test,","NOT_YET_RECRUITING","2025-12-18",{"date":32,"type":33},"2026-01-02","ACTUAL",{"date":35,"type":22},"2026-01-15",{"date":37,"type":22},"2026-12-31",{"name":39,"class":40},"Paracelsus Medical University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":17,"sex":18,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100603979","bone-outcomes-obesity-sunlight-and-trauma-in-children-100603979","NCT07143552","Bone Outcomes, Obesity, Sunlight, and Trauma in Children","A Prospective Case-Control Study of Vitamin D Status, Bone Metabolic Markers, and Overweight in Pediatric Low-Energy Fractures","BOOST","Inclusion Criteria:\n\n* 3-15 years;\n* low-energy trauma;\n* cases = radiographic fracture; controls = no fracture.\n\nExclusion Criteria:\n\n* chronic renal\u002Fliver disease;\n* primary hypo-\u002Fhyperparathyroidism;\n* hypophosphatemic rickets;\n* neuromuscular disorders;\n* corticosteroids\u002Fbisphosphonates;\n* unclear diagnosis\u002Ftreatment.","3 Years","15 Years",{"count":52,"type":22},100,"Prospective case-control study of children (3-15 years) after low-energy trauma. We compare serum bone metabolic markers (25OHD, PTH, ALP, calcium, phosphate), BMI\u002Fpercentile, and dietary calcium intake between fracture and non-fracture presentations. Blood is collected within 7 days (non-fasting; samples on ice for PTH). Primary aim: association of ALP and calcium with fracture status; secondary aims: vitamin D status, BMI percentile, and a composite Bone Risk Score (≥3). Analyses: group comparisons, logistic regression, ROC.",[55,56,57],"Pediatric Fractures","Hypovitaminosis D","Obesity and Overweight",[59,60,61,62,63,64,65],"Vitamin D","Alkaline phosphatase","Calcium","Case-control","bmi","phosphate","Low-energy trauma","RECRUITING","2025-08-26",{"date":69,"type":33},"2025-09-03",{"date":71,"type":33},"2024-07-01",{"date":73,"type":22},"2026-09",{"name":39,"class":40},2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":91,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100407932","a-prospective-randomised-multi---center-trial-on-the-repair-of-large-hiatal-hernias-absorbable-mesh-vs-pledgeted-sutures-vs-sutures-only-100407932","NCT04591860","A Prospective Randomised Multi - Center Trial on the Repair of Large Hiatal Hernias: Absorbable Mesh vs. Pledgeted Sutures vs. Sutures Only","A Prospective Randomised Multi - Center Trial on the Repair of Large Hiatal Hernias With Sutures Versus Pledgeted Sutures Versus Absorbable Mesh","Inclusion Criteria:\n\n* Patients with a large hiatal hernia - admitted for surgery (laparoscopic \u002F robot-assisted)\n* Written informed consent\n* ≥ 18 years of age\n* Hiatal hernia documented by barium x-ray and\u002For gastroscopy and\u002For manometry by one or more of the following criteria:\n\n  * \\> 5cm hiatal hernia\n  * 1\u002F3 of the stomach in the thorax\n\nExclusion Criteria:\n\n* Lack of patient consent for study participation\n* Lack of consent to study due to linguistic or mental incomprehension\n* Patients in poor general condition (lack of anesthesia ability)\n* Pregnancy\n* Prior surgery on the stomach or gastroesophageal junction\n* Simultaneous surgery because of another illness",{"count":84,"type":22},165,"INTERVENTIONAL",[87],"NA","A prospective randomised multi - center trial on the repair of large hiatal hernias with sutures versus pledgeted sutures versus absorbable mesh\n\nThe primary objective of the present trial is to compare the hiatal hernia recurrence rate between three different methods of cruroplasty in large hiatal hernias: hiatal closure with sutures versus pledgeted sutures versus absorbable mesh (Phasix™ST mesh).\n\nThe duration of the study is not limited and depends on the number of cases planned. After enrollment in the study, patients will be followed - up with standardized questionnaires and gastroscopy at 6 months, 1 year, 3 years and 5 years after surgery.",[90],"Hiatal Hernia",[92,93,94,95],"hiatal hernia","pledgets","mesh","hernia recurrence","2024-04-01",{"date":98,"type":33},"2024-04-02",{"date":100,"type":22},"2024-05-01",{"date":102,"type":22},"2027-05-01",{"name":39,"class":40},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":85,"phases":113,"briefSummary":114,"conditions":115,"keywords":121,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100522426","framed-infrainguinal-venous-bypass-versus-conventional-autologous-bypass-trial-100522426","NCT06082466","FRAMED Infrainguinal Venous Bypass Versus Conventional Autologous Bypass Trial","Framed IVB","Inclusion Criteria\n\n* Age at least 18 years\n* Informed consent form with signature\n* Rutherford Category 3 (\\\u003C200m) or chronic critical ischemia (Rutherford Category 4-6)\n* Assured inflow and recipient artery.\n\nExclusion Criteria\n\n* Pregnant or breastfeeding women\n* Active infection or sepsis\n* Acute ischemia\n* Endovascular procedure in the region to be treated.\n* Vein with outer diameter \\\u003C3.5 mm or \\>8 mm under pressure.\n* Spliced Veins.\n* Known allergy to the cobalt-chromium alloy (ASTM 1058) or its components (Cobalt-Chromium-Iron-Nickel-Molybdenum).\n* Vasculitis\n* Coagulopathy\n* Radiation therapy near the anastomosis",{"count":112,"type":22},110,[87],"The purpose of this clinical trial is to analyze patency after autologous infrainguinal bypass surgery in patients receiving a venous conduit versus a covered venous conduit.",[116,117,118,119,120],"Peripheral Arterial Occlusive Disease","Femoropopliteal Artery Occlusion","Femoropopliteal Stenosis","Critical Limb-Threatening Ischemia","Claudication, Intermittent",[122,123,124],"Extraluminal Bypass Stenting","Autologous Vein Graft","Bypass Extremity Graft","2023-11-20",{"date":127,"type":33},"2023-11-21",{"date":129,"type":33},"2023-09-11",{"date":131,"type":22},"2027-09",{"name":39,"class":40},1,""]